



**Chi-Med and Nestlé Health Science
establish Joint Venture**

Press Cuttings Book

29 November 2012

News wires

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: Bloomberg (11:27)

Date: 28 November 2012

Nestle Forms Botanical Medicines Joint Venture With Chi-Med (2)

2012-11-28 11:27:21.306 GMT

(Updates with Chi-Med shares in fifth paragraph.)

By Makiko Kitamura and Dermot Doherty

Nov. 28 (Bloomberg) -- Nestle SA and Hutchison China Meditech Ltd., the drugmaker controlled by Hong Kong billionaire Li Ka-shing, agreed to form an alliance to develop gastro- intestinal treatments based on traditional Chinese medicines.

Nestle Health Science and Chi-Med will each own half of the Nutrition Science Partners Ltd. venture, the companies said in a statement today. NSP will also take on an experimental medicine known as HMPL-004 and oversee late-stage clinical trials on treatments for ulcerative colitis and Crohn's disease.

The collaboration gives Vevey, Switzerland-based Nestle exclusive access to Chi-Med's botanical library of more than

1,500 purified natural products and 50,000 extracts from medicinal plants. Chi-Med entered an agreement with AstraZeneca Plc in December to develop an experimental cancer drug.

"We believe traditional Chinese medicine has a real potential to become part of innovative solutions," Luis Cantarell, CEO of Nestle Health Science, said on a conference call.

Nestle shares rose 0.7 percent to 60.30 Swiss francs at 12:20 p.m. in Zurich trading, for a gain this year of 12 percent. Chi-Med advanced 5.8 percent in London, the most in almost four months, for a gain this year of 43 percent.

Brain Health

The partnership may extend into metabolic diseases and brain health, the companies said. The venture will also tap the capabilities of Prometheus Laboratories Inc., which Nestle bought last year. Prometheus focuses on tests and treatments for cancer and gastroenterology.

"As an old Nescafe ad used to say: 'One thing leads to another,'" Cantarell said.

The joint venture's initial focus will be on the U.S., and Chi-Med has already been discussing late-stage testing of HMPL-

004 with regulators. The third and final phase of testing is expected to begin "early next year." The companies didn't disclose the amount of investment in the collaboration.

"Nestle seems to us to be a perfect partner for HMPL- 004," given its investment potential in research and development, Savvas Neophytou, an analyst at Panmure Gordon, wrote in a research note.

"Although the deal structure revolves originally around gastrointestinal assets, it should be noted that a broader collaboration on the entire botanicals portfolio could materialize in coming years," he wrote.

Nestle established the health science business early last year to develop personalized nutrition treatments for conditions such as diabetes, obesity and heart disease.

For Related News and Information:

Top Health stories: HTOP <GO>

For Bloomberg Industries pharmaceuticals research:

BI PHRM <GO>

Company financial analysis: HCM LN <Equity> FA <GO>

--With assistance from Clementine Fletcher in London. Editors:

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: Bloomberg (09:59)

Date: 28 November 2012

Nestle Forms Botanical Medicines Joint Venture With Chi-Med (1)

(Updates with Nestle comment in fourth paragraph.)

By Makiko Kitamura and Dermot Doherty

Nov. 28 (Bloomberg) -- Nestle SA and Hutchison China Meditech Ltd., the drugmaker controlled by Hong Kong billionaire Li Ka-shing, agreed to form an alliance to develop gastro-intestinal treatments based on traditional Chinese medicines.

Nestle Health Science and Chi-Med will each own half of the venture, Nutrition Science Partners Ltd., the companies said in a statement today. NSP will also take on an experimental medicine known as HMPL-004 and oversee late-stage clinical trials for ulcerative colitis and Crohn's disease.

The collaboration gives Vevey, Switzerland-based Nestle exclusive access to Chi-Med's botanical library of more than

1,500 purified natural products and 50,000 extracts from medicinal plants. Chi-Med entered an agreement with AstraZeneca Plc in December to develop an experimental cancer drug.

"We believe traditional Chinese medicine has a real potential to become part of innovative solutions," Luis Cantarell, CEO of Nestle Health Science, said on a conference call.

Nestle shares rose 0.7 percent to 60.30 Swiss francs at 10:52 a.m. in Zurich trading. The stock has gained about 12 percent this year.

Brain Health

While the collaboration will focus initially on oral drugs, the venture will also seek to develop other traditional medicine products such as medical food, Cantarell said. The partnership may extend into metabolic diseases and brain health, the companies said. The venture will also tap the capabilities of Prometheus Laboratories Inc., which Nestle bought last year.

Prometheus focuses on tests and treatments for cancer and gastroenterology.

"Nestle seems to us to be a perfect partner for HMPL- 004," given its investment potential in research and development, Savvas Neophytou, an analyst at Panmure Gordon, wrote in a research note.

"Although the deal structure revolves originally around gastrointestinal assets, it should be noted that a broader collaboration on the entire botanicals portfolio could materialize in coming years," he wrote.

The joint venture's initial focus will be on the U.S. and the Chi-Med has already been discussing late-stage testing of HMPL-004 with regulators. The third and final phase of testing is expected to begin "early next year." The companies didn't disclose the amount of investment in the collaboration.

"As an old Nescafe ad used to say: 'One thing leads to another,'" Cantarell said.

Nestle established the health science business early last year to develop personalized nutrition treatments for conditions such as diabetes, obesity or heart disease.

For Related News and Information:

Top Health stories: HTOP <GO>

For Bloomberg Industries pharmaceuticals research:

BI PHRM <GO>

Company financial analysis: HCM LN <Equity> FA <GO>

--With assistance from Clementine Fletcher in London. Editors:

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: Bloomberg (07:55)

Date: 28 November 2012

Nestle Forms Botanical Medicines Joint Venture With Chi-Med

2012-11-28 07:55:10.317 GMT

By Makiko Kitamura

Nov. 28 (Bloomberg) -- Nestle SA and Hutchison China Meditech Ltd., the drugmaker controlled by Hong Kong billionaire Li Ka-shing, agreed to form a joint venture to develop gastro- intestinal treatments based on traditional Chinese medicines.

Nestle Health Science and Chi-Med will each own half of the new company, Nutrition Science Partners Ltd., the companies said in a statement today. NSP will also take on an experimental medicine known as HMPL-004 and oversee late-stage clinical trials for ulcerative colitis and Crohn's disease.

The collaboration gives Nestle exclusive access to Chi- Med's botanical library of more than 1,500 purified natural products and 50,000 extracts from medicinal plants. Chi-Med entered an agreement with AstraZeneca Plc in December to develop an experimental cancer drug.

The deal "provides Nestle Health Science with an opportunity to develop and commercialize truly innovative and scientifically validated botanical-based nutrition solutions for personalized healthcare," Luis Cantarell, President and CEO of Nestlé Health Science, said in the statement.

For Related News and Information:

Top Health stories: HTOP <GO>

News on Pharmaceutical research: BDRG <GO> Company financial analysis: HCM LN <Equity> FA <GO>

--Editors: Marthe Fourcade, David Risser.

To contact the reporter on this story:

Makiko Kitamura in London at +44-20-3525-8467 or mkitamura1@bloomberg.net

To contact the editor responsible for this story:

Phil Serafino at +33-1-5530-6277 or
pserafino@bloomberg.net

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: Dow Jones (09:06)

Date: 28 November 2012

Chi-Med Sets Up Health Science JV With Nestle

LONDON--**Hutchison China Meditech Ltd.** (HCM.LN) or Chi-Med, a China-based pharmaceutical group, and Nestle Health Science SA, a fully-owned subsidiary of Nestlé SA, Wednesday announced a 50-50 joint venture, Nutrition Science Partners Ltd, to develop gastrointestinal botanical medicines and nutritional products.

MAIN FACTS:

- Plans to research and develop a pipeline medicines products through access to best-in-class Traditional Chinese Medicine library and discovery platform

- Will progress HMPL-004, the lead candidate, through Phase III trials for ulcerative colitis and Crohn's disease

- May in the future expand into the metabolic disease and brain health areas.

- Nestlé Health Science will make an initial capital investment in return for its 50% shareholding; Chi-Med will provide exclusive rights to its extensive botanical library and well-established botanical R&D platform, in the field of gastrointestinal disease.

- Chi-Med shares at 0906 GMT up 15 pence or 3.5% at 445 pence valuing the company at GBP224 million.

- Write to Ed Ballard at ed.ballard@dowjones.com

Client: Chi Med
Source: Stock Market Wire (Web)
Date: 28 November 2012

Chi-Med and Nestle Health Science in JV

StockMarketWire.com - Nestlé Health Science and Chi-Med have agreed to form a 50-50 joint venture to be named Nutrition Science Partners Limited. The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and nutritional products derived from botanical plant origins. NSP will focus on gastrointestinal indications, and may in the future expand into the metabolic disease and brain health areas. At 8:08am: [LON:HCM] share price was +10p at 440p Story provided by StockMarketWire.com

[sourcelink]

<http://www.stockmarketwire.com/article/4492910/Chi-Med-and-Nestl-Health-Science-in-JV.html>

[/sourcelink]

Nationals

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: Financial Times

Date: 28 November 2012

Nestlé health unit seeks Chinese remedy

By Louise Lucas in London

Nestlé has agreed a tie-up with a traditional Chinese medicine company owned by Hong Kong billionaire Li Ka-shing in an unusual alliance between the ancient and modern worlds of healthcare and nutrition.

The pairing together of Chinese medicine, with roots going back two millennia, and the world's biggest food producer comes as companies increasingly see innovation in ancient practices such as pharmaceuticals and agriculture.

The joint venture with Hong Kong-based **Chi-Med** will give the Swiss food group access to the healthcare and pharmaceutical group's library of 50,000 extracts from more than 1,200 herbal plants.

Swiss-based Nestlé, which set up its wholly-owned health science unit nearly two years ago with a mandate to develop nutritional ways of dealing with chronic diseases, heralded the new partnership as "a milestone".

"For us, we believe that traditional Chinese medicine, coming from the East, has real potential to be part of the innovative solutions," said Luis Cantarell, chief executive of Nestlé Health Science.

"I believe we might be the first, or one of the first, in this kind of thing." The 50/50 joint venture will begin with an undisclosed capital investment from Nestlé, with more funds being invested as compounds and trials progress.

The first treatment under development is for irritable bowel syndrome, which is expected to yield results around 2014. Depending how these results pan out, it would then be commercialised as a drug.

Chi-Med entered an agreement with AstraZeneca last year to develop an experimental cancer drug.

Client: Chi Med
Source: The Times (Main)
Date: 29 November 2012
Page: 65
Reach: 407720
Size: 105cm2
Value: 3200.4

Citigate
Dewe Rogerson



Martin Waller Tempus

Hutchison China MediTech

One does not immediately associate Nestlé with healthcare, but the multinational has a business, Nestlé Health Science, that is almost two years old, boasts sales of about \$2 billion and is charged with bringing compounds to market that are based, in the broadest sense, on nutritional health.

Hutchison China MediTech (Chi-Med to its friends and a long-time favourite of this column) develops Chinese botanical products into pharmaceuticals that can be sold in the West. This is supported by the main activities of the group: the provision of its own pharmaceuticals to the Chinese healthcare market.

But that business is not able to generate the sort of sums needed to take the botanicals to market. So Nestlé has agreed a joint venture with Chi-Med that will take its most promising compound, the snappily titled HMPL-004, and provide the estimated \$150 million to \$200 million needed to put it through Phase-III clinical trials.

Ordinarily, Chi-Med would license the drug. A joint venture not only allows a company to retain more of the eventual profits but also allows other products to be developed via the same route.

The compound treats ulcerative

where any meaningful multiple can be put on the shares. Not for widows and orphans, then, but a good speculative punt.

colitis and Crohn's disease, a market annually worth \$6 billion or more. Even a fraction of this revenue would be transformational for Chi-Med, even before any other product comes to market (it did a licensing deal last December with AstraZeneca for an unrelated cancer treatment, although it is at an earlier development stage).

Chi-Med shares have risen 43 per cent this year, after another 25p rise to 455p yesterday. The company is profitable, just, but a long way from

Client: Chi Med
Source: The Times (Main)
Date: 29 November 2012
Page: 54
Reach: 407720
Size: 22cm2
Value: 670.56

Citigate
Dewe Rogerson

Need to know

Health

Smith & Nephew: S&N will jump into one of the fastest-growing healthcare markets with a \$782 million deal to buy Healthpoint Biotherapeutics, a Texas-based wound-care business. **Page 57**

Hutchison China MediTech: The company, which concentrates on Chinese traditional medicines, has struck a deal with Nestlé to bring a treatment for ulcerative colitis to the West. **Tempus, page 65**

Client: Chi Med
Source: The Guardian (Main)
Date: 29 November 2012
Page: 30
Reach: 204271
Size: 62cm2
Value: 886.6

Citigate
Dewe Rogerson

Business analysis

Pharmaceuticals

Chocolate and gastrointestinal medical research - it could be an interesting mix


The great Anthony Bolton of Fidelity hasn't had much luck finding winners in China but at least a Chinese company he found on the London market is making excellent progress. The firm, where Bolton's China fund has picked up a 5% holding, is Hutchison China MediTech.

The excitement here is usually concentrated on a booming business distributing pharmaceuticals plus healthcare and organic products in China. But Chi-Med, as it's known, also has a drug research and development division. Analysts often value this at roughly zero but may have to rethink after yesterday's intriguing deal.

Chi-Med is forming a joint venture with Nestlé to put a treatment for ulcerative colitis and Crohn's disease through final-stage clinical trials. Chi-Med contributes the drug and expertise while the Swiss company coughs up the cash for the tests. You can understand why Chi-Med is generating a buzz.

Client: Chi Med
Source: The Daily Telegraph (Business)
Date: 29 November 2012
Page: 4
Reach: 584089
Size: 354cm2
Value: 11377.56

Citigate
Dewe Rogerson



Weighing it up Nestle goes herbal

NESTLE has agreed to launch a "milestone" joint-venture with a traditional Chinese medicine company controlled by Hong

Kong billionaire Li Ka-shing. The Swiss food giant will team up with healthcare company Hutchison China MediTech (Chi-

Med), taking advantage of the Asian group's library of 50,000 extracts from more than 1,200 plants.

Client: Chi Med
Source: City AM (Main)
Date: 29 November 2012
Page: 20
Reach: 128785
Size: 146cm2
Value: 1575.34

Citigate
Dewe Rogerson

Nestle turns to China in bid for herbal remedy

BY JAMES TITCOMB

THE HEALTH unit of Nestle yesterday launched a tie-up with a company that specialises in traditional Chinese medicine in a bid to develop novel medicines derived from plants.

Nestle Health Science is expected to plough at least £100m into the joint venture with London-listed Chi-Med, which creates a new company called Nutrition Science Partners (NSP).

Chi-Med, which has years of experience in alternative medicine, will contribute its knowledge and facilities, while Nestle is throwing its weight behind the joint venture with a cash investment.

This is estimated at \$150-200m (£94-£125m), although sources close to the deal suggested the figure could be higher than this. The companies believe the marriage of Nestle's backing with Chi-Med's herbal treatments will result in new remedies.

The parties will each have a 50 per cent stake in the venture. NSP will focus on gastro-intestinal treat-

ments – such as those for irritable bowel syndrome – and may expand into the metabolic disease and brain health areas, the new company said.

Shares in Chi-Med – which is majority owned by Chinese conglomerate Hutchison Whampoa – rose almost five per cent in London yesterday.

Christian Hogg, the firm's chief executive, said that Chi-Med "has invested for many years in developing novel medicines for the global market derived from proven botanical sources" and that it was "a leading company in the world in this field".



Client: Chi Med
Source: Evening Standard (Main)
Date: 28 November 2012
Page: 43
Reach: 699338
Size: 66cm2
Value: 4137.54

Citigate
Dewe Rogerson

Chi-Med chimes well with big-hitters

THIS column has had a soft spot for Chi-Med since it floated back in the far-off days when the London market used to do new issues. It has had some bumps on the way, but the mix of business – original drug research, development of treatments derived from traditional Chinese medicines, and the cash-generating distribution of consumer health products in China – seems to be working.

The problem facing small drug companies is finding the money to take their promising discoveries through the costly and fraught testing process, so the trick is to arouse the interests of one of the majors and get it to foot the

bill. Thus last year the company did a deal with AstraZeneca for joint development of a cancer treatment, and today it announced what looks like an even bigger deal with Nestlé whereby they will form a 50-50 joint venture for stage three testing of a treatment for Crohn's disease and ulcerative colitis.

Neither of these guarantees that the company is actually on to a winner. But it is hugely encouraging that first AstraZeneca and now Nestlé both think the company has products worth putting money into.

Press Cutting

Client: Chi-Med

Publication: BBC News

Date: 29 November 2012

Nestle in Chinese medicine deal with Li Ka-Shing's firm

Nestle, the world's biggest food group, has agreed a deal to develop treatments based on traditional Chinese medicines.

It will set up a joint venture with Hutchison China MediTech, controlled by Hong Kong billionaire Li Ka-Shing.

The deal will give Nestle access to more than 50,000 extracts used in the manufacture of Chinese medicines.

The deal comes as the global market for Chinese medicines expands. It is valued at more than \$83bn (£52bn) by the World Health Organization.

In China alone, the industry produced almost \$48bn worth of such medicines in 2010.

That was up almost 30% from the year before.

"We believe traditional Chinese medicine has a real potential to become part of innovative solutions," Luis Cantarell, chief executive of Nestle Health Science, was quoted as saying on a conference call by the Financial Times and the Bloomberg News agency.

The joint venture, called Nutrition Science Partners Limited (NSP), will develop and manufacture nutritional and medicinal products.

It will initially focus on developing gastro-intestinal products, but may "may in the future expand into the metabolic disease and brain health areas", Nestle said in a statement.

Trade Press

Press Cutting

Citigate
Dewe Rogerson

Client: Chi-Med

Publication: BioCentury Extra

Date: 28 November 2012

BioCentury Extra

ESSENTIAL NEWS FOR BIOTECH & PHARMA

Chi-Med, Nestle to form JV for plant-based products

Hutchison China MediTech Ltd. (LSE:HCM) and the Nestle Health Science S.A. subsidiary of Nestle S.A. (SIX:NESN) are forming a 50/50 JV, Nutrition Science Partners Ltd., to develop and commercialize worldwide plant-derived natural products for gastrointestinal indications. The deal includes Hutchinson's HMPL-004, an oral inflammatory cytokine inhibitor that is slated to enter Phase III testing for ulcerative colitis and Crohn's disease early next year.

Nestle will provide undisclosed initial funding for the JV, which is eligible for undisclosed milestones and royalties from Nestle. Nestle will also contribute "competencies in nutritional sciences, diagnostics and commercial capabilities." Hutchinson will provide exclusive rights to its compound library. The partners said the JV may also expand into "metabolic disease and brain health areas." Luis Cantarell, president and CEO of Nestle Health Science, will be the JV's chairman. Hutchison CEO Christian Hogg will be a director and general manager of the JV. Hutchison was up 25p to 455p on Wednesday.

Client: Chi-Med

Publication: Scrip

Date: 28 November 2012



Nestlé forms JV to develop botanical drugs with Chi-Med

Today

Sukaina Virji

Nestlé's health science subsidiary, set up last year, has formed a 50/50 joint venture with Hutchison China MediTech (Chi-Med) aimed at developing prescription medicines from botanical plant origins.

Nestlé Health Science and Chi-Med's JV is to be named Nutrition Science Partners (NSP). It will initially focus on gastrointestinal indications but the intention is to expand into the metabolic disease and brain health areas in the future, Chi-Med's CEO Christian Hogg told *Scrip*.

"Whilst Nestlé Health Science will bring unique competencies in nutritional sciences, diagnostics and commercial capabilities, Chi-Med will provide their best-in-class Traditional Chinese Medicine library and discovery platform, which will be the basis of NSP's future GI pipeline. The lead candidate HMPL-004 addresses key unmet GI needs for IBD patients," commented Luis Cantarell, president and CEO of Nestlé Health Science.

Nestlé will make an initial capital investment in return for its 50% shareholding in NSP; while Chi-Med will provide exclusive rights to its extensive botanical library and R&D platform, in the field of gastrointestinal disease. This botanical library contains over 1,500 purified natural products and over 50,000 extracts/fractions derived from more than 1,200 different medicinal plants.

NSP will also progress Chi-Med's HMPL-004, a novel, oral therapy for inflammatory bowel disease which is derived from a botanical extract, through Phase III registration trials for ulcerative colitis and Crohn's disease. According to Chi-Med, the clinical efficacy and safety of HMPL-004 in the treatment of IBD has already been demonstrated in more than 400 patients, including Phase IIb trials in North America and Europe.

The Phase III program for HMPL-004 is scheduled to start in early 2013. It will be conducted primarily in the US and Europe and is expected to enrol more than 2,700 patients suffering from ulcerative colitis and Crohn's disease.

HMPL-004 is being developed under the botanical drug guidance pathway which the US FDA published in 2004. It is a rarely-utilised route to approval because it is "complex and convoluted", says Mr Hogg, primarily owing to the nature of botanical products, which have multiple active ingredients. He is aware of only one product, "a topical drug in women's health", that has been approved using the pathway. "Nothing is as far along as HMPL-004, definitely no oral products", he states. "We're pioneering this."

Mr Hogg believes Nestlé was attracted to the botanical nature of Chi-Med's library. "Nestlé is used to growing things in a certain way...coffee, coca. Growing herbs in a tightly regulated manner does not scare them, whereas it would be something new for many big pharma companies."

NSP will be led by its board. Luis Cantarell will be the chairman, and Mr Hogg will be both a director and its first general manager.

NSP will be funded primarily through the initial Nestlé Health Science capital investment and further milestone payments linked to success of clinical and commercial activities.

The seriousness of Nestlé's healthcare intentions was signalled last year when it bought Prometheus Laboratories, a specialty pharmaceutical and diagnostic company, for an undisclosed figure that was rumoured to be up to \$1 billion (scripintelligence.com, 25 May 2011).

International Press

Client: Chi Med
Source: Boursorama (Web)
Date: 28 November 2012

Nestle investit dans la medecine traditionnelle chinoise

Le groupe suisse Nestlé, numéro 1 mondial de l'alimentation, investit dans la médecine traditionnelle chinoise, avec un accord de joint-venture avec le groupe chinois Chi-Med (pharmacie, santé), selon un communiqué publié mercredi.

Les deux groupes ont décidé de créer une nouvelle société appelée Nutrition Science Partners Limited (NSP), détenue à 50/50.

Aucun détail financier de l'opération n'a été divulgué.

NSP va développer et fabriquer de nouveaux produits nutritionnels à base de plantes botaniques.

Cet accord de partenariat va donner accès à la division Nestlé Health Science au secteur de la médecine chinoise traditionnelle, ajoute le communiqué.

NSP va se concentrer sur le secteur gastrointestinal et pourrait dans le futur s'intéresser aussi aux maladie du métabolisme et aux maladies neurologiques.

Le nouvel accord donne accès Nestlé à une banque de données de la médecine traditionnelle chinoise comprenant plus de 50.000 extraits originaires de plus de 1.200 plantes.

"Cet accord de joint-venture donne à Health Science l'opportunité de développer et de commercialiser une nutrition réellement innovative et validée sur le plan scientifique à base de plantes pour des soins adaptés au secteur gastrointestinal", a déclaré Luis Cantarell, directeur général de Nestlé Health Science.

De son côté, Christian Hogg, directeur général de Chi-Med, a déclaré être sûr qu'avec cette joint-venture de "nouveaux produits médicaux et nutritionnels vont pouvoir être mis sur le marché pour le bénéfice des patients et de nos actionnaires".

Hutchison MediPharma Ltd, une filiale de Chi-Med, est déjà actif dans ce secteur et est en train de mettre au point des produits, à prendre oralement, pour calmer des maladies inflammatoires de l'intestin.

Son principal composant est l'andrographis paniculata, une plante utilisée en médecine traditionnelle chinoise.

Des essais cliniques de ce produit seront lancés début 2013, sous l'égide du nouveau partenariat.

[sourcelink]

<http://www.boursorama.com/actualites/nestle-investit-dans-la-medecine-traditionnelle-chinoise-b075ab3aecaa27b47216f6cff>

[/sourcelink]

Client: Chi Med
Source: Agence France Presse
Date: 28 November 2012

Nestle ventures into Chinese medicine with pharma deal

The world's biggest food group Nestle is moving into traditional Chinese medicine by joining forces with Chinese pharma group Chi-Med, the Swiss group said on Wednesday.

The new entity, called Nutrition Science Partners (NSP), is to be owned equally by the two parties, Nestle said in a statement, without revealing any of the financials behind the deal.

NSP will research, develop, make and sell nutritional and medicinal products derived from botanical plants, it said.

The joint venture will also hand Nestle's Health Science division, which is handling the deal, access to Chi-Med's traditional Chinese medicine library, which with more than 50,000 extracts from more than 1,200 different herbal plants is one of the world's largest, the statement said.

Initially, the product focus will be on gastro-intestinal health -- a market worth up to \$6 billion (4.6 billion euros) according to Chi-Med -- but could in future expand into metabolic diseases and brain health, Nestle said.

For Chi-Med, the deal, which is still subject to regulatory approvals, will bring "a stream of novel botanical medicines and nutritional products to market and in so doing build significant value for patients and for our shareholders," company chief executive Christian Hogg said on a conference call.

"Botanical are in the forefront in our view in the search for new medicines," the Chi-Med chief said.

Traditional Chinese plant-based medicines represented between 30 percent and 40 percent of all pharma sales in China, he added.

"This joint venture provides Nestlé Health Science with an opportunity to develop and commercialise truly innovative and scientifically validated botanical-based nutrition for personalised healthcare in gastro-intestinal health," Nestle Health Science head Luis Cantarell said.

mnb/dmj/nl/hd

Client: Chi Med
Source: L'Usine Nouvelle (Web)
Date: 28 November 2012

Nestle se lance dans la medecine traditionnelle chinoise

Le géant suisse de l'agroalimentaire va se lancer dans la médecine traditionnelle chinoise, avec un accord de joint-venture avec le groupe pharmaceutique chinois Chi-Med.

Nestlé, numéro 1 mondial de l'agroalimentaire, vient d'annoncer son intention d'investir dans la médecine traditionnelle chinoise, avec un accord de joint-venture avec le groupe pharmaceutique chinois Chi-Med, selon un communiqué publié le 28 novembre.

Les deux groupes ont décidé de créer une nouvelle société, appelée Nutrition Science Partners Limited (NSP), détenue à parité. Le détail financier de l'opération n'a pas été dévoilé.

NSP devrait développer et fabriquer de nouveaux produits nutritionnels à base de plantes botaniques. « Cet accord de partenariat va donner à la division Nestlé Health Science accès au secteur de la médecine chinoise traditionnelle », ajoute le communiqué, qui précise que NSP va se concentrer sur le secteur gastrointestinal et pourrait dans le futur s'intéresser aussi aux maladies du métabolisme et aux maladies neurologiques.

"Cet accord de joint-venture donne à Health Science l'opportunité de développer et de commercialiser une nutrition réellement innovante et validée sur le plan scientifique à base de plantes pour des soins adaptés au secteur gastrointestinal", a déclaré Luis Cantarell, directeur général de Nestlé Health Science. Le groupe suisse devrait avoir accès à une banque de données de la médecine traditionnelle chinoise comprenant plus de 50 000 extraits originaires de plus de 1 00 plantes.

Des essais cliniques d'un nouveau produit à base d'andrographis paniculata, une plante utilisée en médecine traditionnelle chinoise, pour calmer des maladies inflammatoires de l'intestin, devraient être lancés début 2013, sous l'égide du nouveau partenariat.

[sourcelink]

<http://www.usinenouvelle.com/article/nestle-se-lance-dans-la-medecine-traditionnelle-chinoise.N186960#xtor=RSS-215>

[/sourcelink]

Client: Chi Med
Source: La Tribune (Web)
Date: 28 November 2012

Nestle mise sur la medecine traditionnelle chinoise pour ses produits a base de plantes

Le numéro 1 mondial de l'alimentation a signé avec un accord de joint-venture avec Chi-Med, groupe chinois spécialisé dans la pharmacie et la santé. L'objectif? Développer et fabriquer de nouveaux produits nutritionnels à base de plantes botaniques. Nestlé n'est pas un novice concernant les produits estampillés "bien être". Et visiblement, le groupe souhaite se renforcer sur ce créneau. Mercredi, le numéro un mondial de l'alimentation a annoncé la signature d'un accord de joint-venture avec le groupe chinois Chi-Med, spécialisé dans la pharmacie et la santé. La nouvelle entité s'appellera Nutrition Science Partners Limited (NSP), et sera détenue pour moitié par les deux acteurs. Nestlé n'a pas toutefois levé le voile sur le montant de l'opération.

Avec cet accord, le groupe suisse s'ouvre les portes de la médecine traditionnelle chinoise. Car NSP a vocation à développer et à fabriquer de nouveaux produits nutritionnels à base de plantes botaniques. Plus précisément, la société va se concentrer sur le secteur gastro-intestinal. Il pourrait par la suite s'intéresser aussi aux maladies du métabolisme et aux maladies neurologiques. Avec cette opération, Nestlé aura accès à une banque de données de la médecine traditionnelle chinoise, comprenant plus de 50.000 extraits originaires de plus de 1.200 plantes.

Un marché de 5 à 6 milliards de dollars

Pour Luis Cantarell, à la tête de Nestlé Health Science, cet accord constitue une "opportunité de développer et de commercialiser une nutrition réellement innovative et validée sur le plan scientifique à base de plantes pour des soins adaptés au secteur gastro-intestinal". Il en va de même pour Chi-Med, dont Christian Hogg, son directeur général, voit ici l'occasion de lancer de "nouveaux produits médicaux et nutritionnels". Et ce, pour "le bénéfice des patients et de nos actionnaires".

De fait, les deux partenaires jugent que l'opération peut s'avérer particulièrement lucrative. Christian Hogg a notamment précisé à l'AFP que les "produits destinés à lutter contre les maladies inflammatoires de l'intestin représentent un marché de 5 à 6 milliards de dollars par an sur le plan mondial".

[sourcelink]

<http://www.latribune.fr/entreprises-finance/industrie/agroalimentaire-biens-de-consommation-luxe/20121128trib000733864/ne>

[/sourcelink]

[Journalistname]latribune.fr[/Journalistname]

Client: Chi Med
Source: De Morgen (Web)
Date: 28 November 2012

Nestle actief in traditionele Chinese geneeskunde

Bewerkt door: redactie 28/11/12, 12u54 Bron: afp ? reuters. De Zwitserse voedingsgroep Nestlé investeert nu ook in traditionele Chinese geneeskunde. De groep ging vandaag een joint venture aan met de Chinese farmagigant Chi-Med, om samen een nieuwe onderneming op te richten die gespecialiseerd zal zijn in voedingsproducten op basis van (geneeskrachtige) planten.

Beide partners zullen elk de helft van het kapitaal van Nutrition Science Partners Limited (NSP) controleren, zo luidde het. Financiële details werden niet bekendgemaakt.

Maag- en darmaandoeningen

NSP zal nieuwe producten ontwikkelen en commercialiseren. De nadruk ligt in eerste instantie op maag- en darmaandoeningen. In de toekomst komen daar misschien nog metabolismeziekten of neurologische aandoeningen bij.

In het akkoord is ook voorzien dat Nestlé toegang krijgt tot een gegevensbank van de traditionele Chinese geneeskunde, met meer dan 50.000 extracten, afkomstig van ruim 1.200 planten.

[sourcelink]

<http://www.demorgen.be/dm/nl/996/Economie/article/detail/1540996/2012/11/28/Nestle-actief-in-traditionele-Chinese-genees>

[/sourcelink]

Client: Chi Med
Source: CASH (Web)
Date: 28 November 2012

Nestle grundet Joint Venture in China zur Entwicklung von botanischen Produkten

28.11.2012 08:34

Vevey (awp) - Der Nahrungsmittelkonzern Nestlé hat in China über die Tochtergesellschaft Nestlé Health Science ein Joint Venture (JV) unter dem Namen Nutrition Science Partners Limited (NSP) gegründet. JV-Partner ist die chinesische Healthcare-Gruppe Chi-Med, wobei beide Unternehmen je 50% halten. NSP soll innovative Nahrungsmittel- und medizinische Produkte erforschen, entwickeln, herstellen und vermarkten, welche aus botanischen Pflanzen gewonnen werden, wie Nestlé am Mittwoch mitteilte.

[sourcelink]

<http://feeds.cash.ch/c/32619/f/501852/s/260a0220//0L0Scash0Bch0Cnews0Calle0Crss0Cnestle0lgruendet0ljoint0lventure0l>

[/sourcelink]

Client: Chi Med
Source: De Standaard Online (Web)
Date: 28 November 2012

Nestle wordt actief in traditionele Chinese geneeskunde

De Zwitserse voedingsgroep Nestlé investeert nu ook in traditionele Chinese geneeskunde. De groep ging woensdag een joint venture aan met de Chinese farmagigant Chi-Med, om samen een nieuwe onderneming op te richten die gespecialiseerd zal zijn in voedingsproducten op basis van (geneeskrachtige) planten. Beide partners zullen elk de helft van het kapitaal van Nutrition Science Partners Limited (NSP) controleren, zo luidde het. Financiële details werden niet bekendgemaakt.

NSP zal nieuwe producten ontwikkelen en commercialiseren. De nadruk ligt in eerste instantie op maag- en darmaandoeningen. In de toekomst komen daar misschien nog metabolismeziekten of neurologische aandoeningen bij.

In het akkoord is ook voorzien dat Nestlé toegang krijgt tot een gegevensbank van de traditionele Chinese geneeskunde, met meer dan 50.000 extracten, afkomstig van ruim 1.200 planten.

[sourcelink]

http://www.standaard.be/artikel/detail.aspx?artikelid=DMF20121128_00384448

[/sourcelink]

Client: Chi Med
Source: Het Laatste Nieuws (Web)
Date: 28 November 2012

Nestle actief in traditionele Chinese geneeskunde

De Zwitserse voedingsgroep Nestlé investeert nu ook in traditionele Chinese geneeskunde. De groep ging vandaag een joint venture aan met de Chinese farmagigant Chi-Med, om samen een nieuwe onderneming op te richten die gespecialiseerd zal zijn in voedingsproducten op basis van (geneeskrachtige) planten.

Beide partners zullen elk de helft van het kapitaal van Nutrition Science Partners Limited (NSP) controleren, zo luidde het. Financiële details werden niet bekendgemaakt.

Maag- en darmaandoeningen

NSP zal nieuwe producten ontwikkelen en commercialiseren. De nadruk ligt in eerste instantie op maag- en darmaandoeningen. In de toekomst komen daar misschien nog metabolismeziekten of neurologische aandoeningen bij.

In het akkoord is ook voorzien dat Nestlé toegang krijgt tot een gegevensbank van de traditionele Chinese geneeskunde, met meer dan 50.000 extracten, afkomstig van ruim 1.200 planten.

Lees ook

Wat vind jij van dit nieuws?

Rapporteer een fout in het artikel aan onze redactie

Meer over

gerelateerd nieuws

Nestlé noteert omzetwinst dankzij groeilanden

Straffe actie Nestlé: 10.000 pond voor klant die 'juiste' chocoladereep koopt

Imtech schrapt 70 banen in Brusselse afdeling

Meer over

RSS (wat is RSS?)

De krant

© 2012 De Persgroep Digital - Alle rechten voorbehouden.

Onze Franstalige nieuwssite www.7sur7.be.

Volg het nieuws op onze zustersite in Nederland

www.ad.nl.

[sourcelink]